Advanced Quantitative Imaging Techniques for Personalized Radiotherapy and Lung Toxicity Avoidance

This activity provides an in-depth exploration of advanced quantitative imaging techniques for personalized radiotherapy, focusing on addressing barriers to clinical implementation and improving the management of lung toxicity. Attendees will be introduced to the latest developments in quantitative imaging modalities, including their applications in radiotherapy treatment planning, response assessment, and functional lung avoidance. The activity covers specific use cases in brain and head and neck malignancies, as well as lung cancer radiotherapy. Discussions will address quality assurance issues, accessibility, reproducibility, and the integration of artificial intelligence (AI) and automated workflows. The activity reviews state-of-the-art technologies such as SPECT/PET/MR/CT imaging, 4DCT ventilation, Dual Energy CT perfusion, and 4D ventilation/perfusion PET, and their role in optimizing radiotherapy planning while minimizing lung toxicity. Specifically, the technologies reviewed will include SPECT/CT imaging, 4DCT ventilation, Dual Energy CT perfusion, and 4D ventilation/perfusion PET. The application of these technologies in defining functional lung volumes and their advantages/disadvantages are reviewed. The applicability and experience of applying these techniques in the radiotherapy workflow for functional lung avoidance are also evaluated.

Topics:

  1. Dual Energy CT and SPECT for Functional Lung Assessment
    Houda Bahig, MD, PhD
  2. Implementation of Quantitative Imaging Modalities for Brain Tumors to Guide RT Targeting 
    Hui-Kuo George Shu, MD, PhD, FASTRO 
  3. V/Q PET for Functional Lung Assessment and Avoidance 
    Nicholas Bucknell, MBBS 
  4. Development of "Personalized Radiotherapy" Techniques through the Incorporation of Novel Imaging Methodologies 
    Clifton David Fuller, MD, PhD
  5. QA Issues with Widespread Implementation of Quantitative Imaging Modalities  
    Michael V Knopp, MD, PhD

This activity is available from January 16, 2024, through 11:59 p.m. Eastern time on December 31, 2025. 

This activity was originally recorded at the 2023 ASTRO Annual Meeting.

Target Audience

The activity is designed to meet the interests of radiation oncologists, physicists, radiation therapists, and radiation dosimetrists. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain different imaging techniques available for functional lung assessment, and specific advantages and disadvantages in clinical practice.
  • Describe functional lung assessment and functional lung avoidance techniques during radiotherapy.
  • Discuss available techniques that can be used to optimize lung radiotherapy planning with functional lung avoidance.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 2.00 Certificate of Attendance
    This activity was designated for 2.00 AMA PRA Category 1 Credit™.
Course opens: 
01/16/2024
Course expires: 
12/31/2025
Cost:
$229.00
Rating: 
0

Shankar Siva, PhD, MBBS, FRANZCR, is employed by the Peter MacCallum Cancer Centre. Dr. Siva sits on the Advisory Board of AstraZeneca. Dr. Siva receives research funding for his institution from Varian Medical Systems and Reflexion Medical Systems. Dr. Siva serves in a leadership role with the following entities: IASLC (ART Committee Member) and the Radiosurgery Society (Advisor to the Board of Directors)

Yevgeniy Vinogradskiy, PhD, is employed by Thomas Jefferson University. Dr. Vinogradskiy receives research funding from the NIH and MIM Software. Dr. Vinogradskiy serves in a leadership role with AAPM as Chair of the Multi-lesion SRS Task Group.    

Jeffrey Buchsbaum, MD, PhD, MS, FASTRO, AM, is employed by NCI. 

Houda Bahig, MD, PhD, is employed by Centre hospitalier de l'Université de Montréal. Dr. Bahig receives research funding from Varian Medical Systems. Dr. Bahig receives research funding for her institution and sits on the advisory board of AstraZeneca. Dr. Bahig receives honoraria from Sanofi. 

Hui-Kuo George Shu, MD, PhD, FASTRO, is employed by Winship Cancer Institute of Emory University, Department of Radiation Oncology. Dr. Shu receives research funding from Novocure and Denovo Biopharma. Dr. Shu owns stock in Gilead Sciences and Akebia Therapeutics. Dr. Shu serves in a leadership position with the NCI-QIRT Interest Group (Co-chair).   

Nicholas Bucknell, MBBS, is employed by the Peter MacCallum Cancer Centre and by Sir Charles Gairdner Hospital. He is an independent contractor with Icon Integrated Cancer Center. Dr. Bucknell receives honoraria from AstraZeneca and Merck. 

Clifton David Fuller, MD, PhD, is employed by The University of Texas MD Anderson Cancer Center. Dr. Fuller receives honoraria from ESTRO and Emory University. He also receives honoraria and serves as a committee member with AAPM.  He is a task force member with NRG Oncology and sits on the advisory board of Varian/Siemens Healthineers. He receives research funding from Philips Medical Systems, Elekta AB, Oncospace, Inc., and the NIH. He serves as a committee member for the University of Texas System Shine Academy. He also serves as an Editorial Board Member of the American Society of Clinical Oncology. 

Michael V. Knopp, MD, PhD, is employed by The Ohio State University Wexner Medical Center. 

The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.

 

Disclosure link: 
Committee Disclosures

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification. 

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 2.00 Certificate of Attendance
    This activity was designated for 2.00 AMA PRA Category 1 Credit™.

Price

Cost:
$229.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

Nonmember: $229
Member: $149
Member-in-training: $79

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.

Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.

The course and its materials will only be available on the ASTRO website until December 31, 2025, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.